Overview
- Reports from Axios, the Wall Street Journal and Endpoints say the administration is close to agreements with Eli Lilly and Novo Nordisk that would pair lower starter-dose prices with Medicare coverage in some cases.
- The lowest dose of Novo Nordisk’s Wegovy would be offered at about $149 per month through TrumpRx and Lilly’s Zepbound at about $299 for the starting dose, according to the Wall Street Journal.
- ABC News, citing a source familiar, said a month’s supply under the pending agreements would cost roughly $149, with an announcement expected as soon as this week.
- White House spokeswoman Karoline Leavitt declined to confirm details and reiterated the administration’s focus on lowering drug prices; Novo Nordisk said discussions are constructive and Lilly said talks are ongoing.
- Medicare already covers GLP-1 medicines for conditions like diabetes and heart disease, and the reported deal could broaden access for seniors and potentially extend to Medicaid coverage, per the Wall Street Journal.